Dilemmas in managing prostate carcinoma (Part II): Metastatic disease

F. R. Ahmann

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Prostate cancer is highly prevalent, but the incidence of clinical significance is low. No successful screening technique for localized disease has been found. Because the natural progression of the disease is highly variable, therapeutic decisions can be made only after biopsy, careful histologic study, and clinical and pathologic staging: Men over age 65 with stage A1 disease need no treatment unless the tumor is poorly differentiated. Men with stage A2 and B1 disease are potentially curable after either radical prostatectomy or radiotherapy. Men with stage C and D disease should be regarded as incurable. They are not good candidates for surgery or radiotherapy, although the latter can be successful in palliating local symptoms. Sixty to 80% of stages C and D patients will obtain a subjective and objective remission to androgen suppression. There are no significantly effective second-line systemic therapies. Patients with prostatic carcinoma are susceptible to a number of malignancy-related complications, which have not been fully appreciated. Because of the numerous variables and complications typical of prostatic carcinoma, patients can frequently benefit from evaluation and follow-up by physicians experienced with this malignancy.

Original languageEnglish (US)
Pages (from-to)61-72
Number of pages12
Issue number9
StatePublished - 1985

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Dilemmas in managing prostate carcinoma (Part II): Metastatic disease'. Together they form a unique fingerprint.

Cite this